cGvHD Clinical Trial
Official title:
A Multicenter, Single-arm, Open-label, Phase II Clinical Study. This Study Consisting of Part A and Part B to Evaluate the Efficacy and Safety of ABSK021 (Pimicotinib) in Patients With Chronic Graft Versus Host Disease
This is a multicenter, single arm, open label phase II clinical study in China. This study will evaluate the efficacy and safety of ABSK021 (Pimicotinib) in the treatment of patients with cGvHD who failed first-line therapy.
This is a phase II, open-label study to evaluate safety, tolerability, pharmacokinetics (PK), and clinical benefit of ABSK021 in patients with hormone refractory or relapsed cGvHD. This study consisted of Part A and Part B, all cGvHD patients in this study will receive continuous oral treatment with ABSK021 once a day (QD) in a 28-day cycle, complete the core treatment period and extended treatment period, and receive regular follow-up until the termination of treatment is determined. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01221766 -
Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
|
N/A | |
| Recruiting |
NCT06244628 -
Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD
|
Phase 3 | |
| Withdrawn |
NCT05604742 -
Belimumab for Treatment of cGVHD Following Allo-HCT
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05214066 -
Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
|
Phase 2 | |
| Recruiting |
NCT05919511 -
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
|
||
| Not yet recruiting |
NCT06364319 -
Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
|
Phase 4 |